Telephone-Based Re-education for Hp Eradication

N/ACompletedNCT03193450

First Affiliated Hospital Xi'an Jiaotong University162 enrolled

Overview

It was suggested that the patient compliance plans an important role in the Hp eradication. However, data on whether re-education could improve the eradication rate are lacking. We consider that re-education on patients by telephone during the process of drug administration could increase the eradication rate in Hp infected patients. We hypothesized that telephone re-education during the whole process of drug administration would improve the compliance of patients and ultimately increase the Hp eradication rate.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

162

Conditions

Helicobacter Pylori Infection

Interventions

telephone-based re-educationBEHAVIORAL

Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.

First education at the clinicBEHAVIORAL

Patients will receive an instruction card about the drug administration at the clinic by doctors.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Prior informed consent 2. 18-70 years of age 3. Hp infected patients diagnosed by 13C urea breath test, including digestive ulcer, gastritis with dyspepsia symptoms, family history of gastric cancer, planning to use long-term non-steroidal anti-inflammatory drugs (NSAIDs), or personal request 4. Ability to swallow oral medications 5. No contraindication for the drugs used for Hp eradication 6. Both men and women enrolled in this trial must use adequate barrier birth control during the course of the trial and 4 weeks after the completion of trial Exclusion Criteria: 1. Pregnant or breast-feeding subjects 2. Previous failed treatment of Hp eradication 3. Previous treatment with bismuth salts or antibiotics within 1 month before study enrollment, and treatment with proton pump inhibitor or H2 receptor antagonist within 2 weeks before study enrollment 4. Any disease that could jeopardize the safety of subject and their compliance in the study (e.g. serious liver disease, heart disease, kidney disease, malignant tumor or alcoholism, etc.) 5. Previous upper gastrointestinal surgery 6. Inability to express complaint (e.g. mental disorder, psychoneurosis, unable to cooperation, etc.) 7. Active clinically serious infections, except for Hepatitis B virus and hepatitis C virus infection 8. Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug

Locations (1)

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Outcomes

Primary Outcomes

Hp eradication rate

Eradication rate is the proportion of patients with eradicated-Hp. Hp infection was considered eradicated when negative results were obtained by 13carbon urea breath test at 4-6 weeks after the end of drug administration

Time frame: 4-6 weeks after the end of drug administration

Secondary Outcomes

Symptoms relief rate

The symptoms were recorded according to Gastrointestinal Symptom Rating Scale.

Time frame: 4-6 weeks after the end of drug administration

Adverse events

The terms and grade of adverse events will be presented according to the Common Terminology Criteria for Adverse Events (CTCAE: version 4.0)

Time frame: 4-6 weeks after the end of drug administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.